

Statement of Deficiencies	(X1) Provider/Supplier/CLIA Identification Number 06D0516894	(X3) Date Survey Completed 11/18/2024
Name of Provider or Supplier Wray Community District Hospital	Street Address, City, State 1017 W 7th St, Wray, CO	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D2016	<p>SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c)</p> <p>(a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history.</p> <p>This CONDITION is not met as evidenced by: Based on a routine desk review of the CMS-155 report for proficiency testing performance and email communications with the laboratory administrative director, the laboratory failed to achieve satisfactory performance scores for the American Proficiency Institute proficiency testing for Total Bilirubin for two consecutive PT events, (event 2 in 2024 and event 3 in 2024), see D2096.</p>
D2096	<p>ROUTINE CHEMISTRY CFR(s): 493.841(f)</p>

Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance.

This STANDARD is not met as evidenced by:

Based on a routine desk review of the CMS-155 report for Proficiency Testing (PT), and email communication with the laboratory manager, the laboratory failed to achieve a satisfactory score for Total Bilirubin for event 2 in 2024 and event 3 in 2024. Findings include: 1. A review of the CMS-155 Individual Laboratory Profile on October 24, 2024, at 09:25 AM, revealed the API PT results for Total Bilirubin testing scores for event 2 in 2024 was 60%, and 40% for event 3 in 2024. 2. An email with the laboratory's administrative director on November 12, 2024, at 01:48 PM, confirmed the laboratory failed to achieve satisfactory test performance for Total Bilirubin for event 2 in 2024, and event 3 in 2024.